Home » How It Works

The COC Protocol – How It Works
Diagram of cell breaking down each part's capabilities

Targeting Cancer’s Metabolic Pathways

The COC Protocol is designed to work primarily be restricting the overall ability of cancer cells to take up and use (i.e. ‘metabolize’) energy.

By starving cancer cells of energy substrates, the treatments in the COC Protocol may reduce the capacity of cancer cells to defend themselves against chemotherapy and radiation. The COC protocol may also act on the many dysregulated signaling pathways within cancer cells helping to enable a process called apoptosis, or “programmed cell death,” allowing chemotherapy and radiation to kill cancer cells more effectively. Cancer cells need huge amounts of energy to survive, and the vast majority of cancers use an adaptive process called aerobic glycolysis to generate the excessive energy they need. The COC Protocol may target the various molecular metabolic processes involved in and surrounding aerobic glycolysis, and this may help lower the overall metabolic rate of the cancer cell.

The COC Protocol may work in combination to consistently restrict energy supply and use, while simultaneously preventing cancer cells from adapting and using other pathways to take up energy. As a result, cancer cells become increasingly weaker and less able to take in and use the nutrients (e.g. such as glucose and essential amino acids glutamine and arginine) they need from their surroundings. This makes it more difficult overall for cancer cells to survive, grow, and spread in the body. Gradually, the weakened cells (including more resilient and previously treatment-resistant cells, become more vulnerable to attack from other cell-killing cancer therapies such as radiotherapy, chemotherapy, hormonal therapy, and targeted therapies.

The COC Protocol was developed by scientists for patients with cancer. This is a multiprong approach, supported by peer-reviewed studies around the efficacy of certain treatments to benefit patients with any stage or cancer type.

1 (Kroemer and Pouyssegur, 2008).
2 (Jang et al., 2013).
3 (Jagust et al., 2019).
4 (Andrzejewski et al., 2018; Liu et al., 2016b).
5 (Bradford and Khan, 2013; Chen et al., 2012; Lacerda et al., 2014; Lamb et al., 2015a; Pantziarka et al., 2014)

Patient Eligibility Form

  • This field is for validation purposes and should be left unchanged.